Skip to content
KStart free
AI InfrastructureDefenseQuantumAll studies →

NBIX US Equity

Neurocrine Biosciences IncHealth Care · Biological Products, (No Diagnostic Substances) · CIK 914475 · FY ends Dec 31
$154.23
-0.26 (-0.17%)
USD · as of 2026-08-18 · marketstack

Legal & controls

5 of 5 annual reports readable here

Item 3 and Item 9A as filed · every verdict is the registrant’s own sentence, printed below it · a filing that fails an extraction gate reads “not extracted”

Fiscal yearFiledItem 3ICFRdisclosure controlsmaterial weaknessFiling
2025-12-312026-02-11in the noteseffectiveeffectivenone in Item 9AEDGAR

Item 3 · For a description of our legal proceedings, see Note 15 to the consolidated financial statements, which is incorporated herein by reference. From time to time, we may become subject to other legal proceedings or claims arising in the ordinary course of our business. We currently believe that none of the claims or actions pending against us is likely to have, individually or in the aggregate, a material adverse effect on our business, financial condition, or results of operations. Given the unpredictability inherent in litigation, however, we cannot predict the outcome of these matters.

Item 9A · ICFR · Based on this assessment, management has concluded that our internal control over financial reporting was effective as of December 31, 2025.

Item 9A · disclosure controls · Based on the foregoing, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective at the reasonable assurance level as of the end of the year covered by this report.

2024-12-312025-02-10in the noteseffectiveeffectivenone in Item 9AEDGAR

Item 3 · For a description of our legal proceedings, refer to Note 15 to the consolidated financial statements, which is incorporated herein by reference.

Item 9A · ICFR · Based on this assessment, management has concluded that our internal control over financial reporting was effective as of December 31, 2024.

Item 9A · disclosure controls · Based on the foregoing, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective at the reasonable assurance level.

2023-12-312024-02-09in the noteseffectiveeffectivenone in Item 9AEDGAR

Item 3 · For a description of our legal proceedings, refer to Note 13 to the consolidated financial statements, which is incorporated herein by reference.

Item 9A · ICFR · Based on this assessment, management has concluded that our internal control over financial reporting was effective as of December 31, 2023.

Item 9A · disclosure controls · Based on the foregoing, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective at the reasonable assurance level.

2022-12-312023-02-09not extractedeffectiveeffectivenone in Item 9AEDGAR

Item 9A · ICFR · Based on this assessment, management has concluded that our internal control over financial reporting was effective as of December 31, 2022.

Item 9A · disclosure controls · Based on the foregoing, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective at the reasonable assurance level.

2021-12-312022-02-11not extractedeffectiveeffectivenone in Item 9AEDGAR

Item 9A · ICFR · Based on this assessment, management has concluded that our internal control over financial reporting was effective as of December 31, 2021.

Item 9A · disclosure controls · Based on the foregoing, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective at the reasonable assurance level.

5 of 5 annual reports on record have their filing text cached on this host; the rest are listed with their EDGAR link and no extraction, because this surface never fetches from SEC on a page load.

  • Item 3 and Item 9A are located in the filing HTML already cached on this host and read with the same line-anchored item matcher and largest-gap body disambiguation the filing-narrative pass uses for Item 1A and Item 7 — no fetch, no model, no summarization.
  • A heading is accepted as a section only when it is not a table-of-contents row (a trailing page number), not a quoted reference in prose, and names its own section; the span must then clear a per-item length band and carry readable text after the heading. Anything that fails a gate is served as 'not extracted' with the reason — never as a default value.
  • An effectiveness conclusion is read only from a sentence that names its own control set (disclosure controls and procedures, or internal control over financial reporting) and states an outcome. Conditional sentences — the standard limitations paragraph and forward-looking remediation language — are excluded, because they are hypotheses rather than conclusions.
  • When a filing's own sentences disagree — an effective conclusion beside an unremediated material-weakness disclosure, or two conclusions of opposite sign — no verdict is asserted. A wrong 'controls were effective' reading is worse than no reading.
  • Every verdict is shown beside the verbatim sentence it was read from. The excerpt is the filing's own words, capped at 1,200 characters; the filing itself is one link away.